These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 15251298

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Long-term follow-up of myeloablative allogeneic stem cell transplantation using Campath "in the bag" as T-cell depletion: the Leiden experience.
    Barge RM, Starrenburg CW, Falkenburg JH, Fibbe WE, Marijt EW, Willemze R.
    Bone Marrow Transplant; 2006 Jun; 37(12):1129-34. PubMed ID: 16757974
    [Abstract] [Full Text] [Related]

  • 6. T-cell depleting antibodies: new hope for induction of allograft tolerance in bone marrow transplantation?
    Simpson D.
    BioDrugs; 2003 Jun; 17(3):147-54. PubMed ID: 12749751
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Prevention of graft vs. host disease with alemtuzumab 'in the bag' decreases early toxicity of stem cell transplantation and in multiple myeloma is associated with improved long-term outcome.
    Novitzky N, Thomas V, du Toit C.
    Cytotherapy; 2008 Jun; 10(1):45-53. PubMed ID: 18202974
    [Abstract] [Full Text] [Related]

  • 9. A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.
    Shore T, Harpel J, Schuster MW, Roboz GJ, Leonard JP, Coleman M, Feldman EJ, Silver RT.
    Biol Blood Marrow Transplant; 2006 Aug; 12(8):868-75. PubMed ID: 16864057
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution.
    Klangsinsirikul P, Carter GI, Byrne JL, Hale G, Russell NH.
    Blood; 2002 Apr 01; 99(7):2586-91. PubMed ID: 11895797
    [Abstract] [Full Text] [Related]

  • 14. A comparison of Campath and Thymoglobulin as part of the conditioning before allogeneic hematopoietic stem cell transplantation.
    Norlin AC, Remberger M.
    Eur J Haematol; 2011 Jan 01; 86(1):57-66. PubMed ID: 20942840
    [Abstract] [Full Text] [Related]

  • 15. Engraftment of marrow allografts treated with Campath-1 monoclonal antibodies.
    Naparstek E, Delukina M, Or R, Nagler A, Kapelushnik J, Varadi G, Strauss N, Cividalli G, Aker M, Brautbar C, Waldmann H, Hale G, Slavin S.
    Exp Hematol; 1999 Jul 01; 27(7):1210-8. PubMed ID: 10390197
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection.
    Hale G, Zhang MJ, Bunjes D, Prentice HG, Spence D, Horowitz MM, Barrett AJ, Waldmann H.
    Blood; 1998 Dec 15; 92(12):4581-90. PubMed ID: 9845524
    [Abstract] [Full Text] [Related]

  • 20. Pretransplant conditioning with Campath-1H (alemtuzumab) in pediatric matched unrelated hematopoietic stem cell transplants: an institutional experience.
    Nageswara Rao AA, Kumar R, Altaf S, Gourde JA, Rodriguez V, Khan SP.
    J Pediatr Hematol Oncol; 2012 Mar 15; 34(2):96-100. PubMed ID: 22146532
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.